Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Confirms Second Batch Of Device Clinical Trial Exemptions

Executive Summary

Chinese regulators have added another 359 medical devices to the list of those not needing to undergo clinical investigation in China following feedback from the industry. This second batch of exemptions follows the initial list issued at the end of 2014.

You may also be interested in...



China Proposes Local Trial Exemptions For Another 130 IVDs, 27 Devices

China has proposed expanding its list of IVDs and medical devices that are exempted from the requirement to undergo local clinical trials. The proposal, when finalized, may speed up the registration of affected products by several months. With respect to ongoing trials, manufacturers will have to decide whether they want to continue with these.

Asia Reg Roundup: Updates From China, Taiwan And Korea

An end-of-year flurry of regulatory activity in the Asian medtech markets has kept industry on its toes, with initiatives in China, Taiwan and Korea, among other regions. But as Asia Regulatory Professional Association (ARPA) Secretary Jack Wong and ARQon consultant May Ng observe in this December update for Medtech Insight, governments and companies in certain markets might benefit from a little more pressure in view of the regulatory tasks they face.

China Renews List of Devices Exempt From Clinical Trials

China's Food and Drug Administration is inviting feedback on a new batch of medium- and high-risk medical devices that it intends to exempt from having to undergo local clinical trials. The agency's proposal, if adopted, would make it much easier and less costly for companies that want to place these devices on the Chinese market.

Topics

UsernamePublicRestriction

Register

MT104020

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel